Insider · CIK 0001339498

Craig Adam R

Reports to the SEC for 4 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001339498

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-12	XFORX4 Pharmaceuticals, IncS Sale	Director, Executive Chairman	SSale	−47.4K sh	$4.44	−$211K	328,651
2025-10-29	XFORX4 Pharmaceuticals, Inc · Stock Option (right to buy)A Award	Director, Executive Chairman	AAward	+2.33M sh	—	—	2,329,154
2025-10-23	XFORX4 Pharmaceuticals, IncP Purchase	Director, Executive Chairman	PPurchase	+86.2K sh	$2.90	+$250K	376,087
2025-08-14	XFORX4 Pharmaceuticals, IncA Award	Director, Executive Chairman	AAward	+290K sh	—	—	289,881
2025-08-14	XFORX4 Pharmaceuticals, Inc · Stock Option (right to buy)A Award	Director, Executive Chairman	AAward	+529K sh	—	—	529,201
2025-08-12	XFORX4 Pharmaceuticals, Inc · Stock Option (right to buy)A Award	Director, Executive Chairman	AAward	+1.61M sh	—	—	1,609,873
2023-06-26	CTI BIOPHARMA CORPStock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−450K sh	—	—	0
2023-06-26	CTI BIOPHARMA CORPStock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−600K sh	—	—	0
2023-06-26	CTI BIOPHARMA CORPStock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−470K sh	—	—	0
2023-06-26	CTI BIOPHARMA CORPStock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−475K sh	—	—	0
2023-06-26	CTI BIOPHARMA CORPStock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−2.32M sh	—	—	0
2023-06-26	CTI BIOPHARMA CORPStock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−800K sh	—	—	0
2023-06-26	CTI BIOPHARMA CORPU Disposition from Tender	Director, President and CEO	UDisposition from Tender	−31.5K sh	$9.10	−$286K	0
2023-06-26	CTI BIOPHARMA CORPStock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−1.2M sh	—	—	0
2023-06-26	CTI BIOPHARMA CORPStock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−1.12M sh	—	—	0
2023-06-26	CTI BIOPHARMA CORPStock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−900K sh	—	—	0
2023-03-14	CTI BIOPHARMA CORPStock Option (right to buy)A Award	Director, President and CEO	AAward	+900K sh	—	—	900,000
2023-01-24	CTI BIOPHARMA CORPNon-Qualified Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−83.2K sh	—	—	472,171
2023-01-24	CTI BIOPHARMA CORPNon-Qualified Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−2,117 sh	—	—	470,054
2023-01-24	CTI BIOPHARMA CORPM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+2,117 sh	$0.84	+$1,780.609	31,557
2023-01-24	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−83.2K sh	$6.00	−$499K	29,440
2023-01-24	CTI BIOPHARMA CORPM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+83.2K sh	$0.84	+$70K	112,640
2023-01-24	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−2,117 sh	$6.01	−$12.7K	29,440
2023-01-03	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−84.7K sh	$6.01	−$509K	29,440
2023-01-03	CTI BIOPHARMA CORPM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+84.7K sh	$0.84	+$71.2K	114,123
2023-01-03	CTI BIOPHARMA CORPNon-Qualified Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−84.7K sh	—	—	555,371
2022-12-30	CTI BIOPHARMA CORPNon-Qualified Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−4,400 sh	—	—	640,054
2022-12-30	CTI BIOPHARMA CORPNon-Qualified Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−700 sh	—	—	644,454
2022-12-30	CTI BIOPHARMA CORPNon-Qualified Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−12K sh	—	—	645,154
2022-12-30	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−700 sh	$6.00	−$4,203.5	29,440
2022-12-30	CTI BIOPHARMA CORPM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+700 sh	$0.84	+$588.77	30,140
2022-12-30	CTI BIOPHARMA CORPA Award	Director, President and CEO	AAward	+1,579 sh	$5.11	+$8,066.322	29,440
2022-12-30	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−12K sh	$6.00	−$72K	29,440
2022-12-30	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−4,400 sh	$6.01	−$26.4K	29,440
2022-12-30	CTI BIOPHARMA CORPM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+4,400 sh	$0.84	+$3,700.84	33,840
2022-12-30	CTI BIOPHARMA CORPM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+12K sh	$0.84	+$10.1K	41,440
2022-12-29	CTI BIOPHARMA CORPNon-Qualified Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−13.8K sh	—	—	657,154
2022-12-29	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−13.8K sh	$6.00	−$82.8K	27,861
2022-12-29	CTI BIOPHARMA CORPM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+13.8K sh	$0.84	+$11.6K	41,661
2022-11-10	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−200 sh	$6.00	−$1,201	79,557
2022-11-10	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−5,800 sh	$6.03	−$35K	30,561
2022-11-10	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−2,700 sh	$6.04	−$16.3K	27,861
2022-11-10	CTI BIOPHARMA CORPM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+188K sh	$0.84	+$158K	216,165
2022-11-10	CTI BIOPHARMA CORPNon-Qualified Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−188K sh	—	—	670,954
2022-11-10	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−26.7K sh	$6.01	−$160K	52,857
2022-11-10	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−136K sh	$6.00	−$818K	79,757
2022-11-10	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−100 sh	$6.01	−$601.5	52,757
2022-11-10	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−16.4K sh	$6.02	−$98.7K	36,361
2022-11-09	CTI BIOPHARMA CORPM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+54K sh	$0.84	+$45.4K	81,857
2022-11-09	CTI BIOPHARMA CORPS Sale	Director, President and CEO	SSale	−46.1K sh	$6.00	−$277K	35,757

Recent filings

Accepted (ET)
Aug 134
Craig Adam R0001501697-26-000069
SEC(opens sec.gov)
Oct 314
Craig Adam R0001339498-25-000004
SEC(opens sec.gov)
Oct 274
Craig Adam R0001501697-25-000035
SEC(opens sec.gov)
Aug 144
Craig Adam R0001628280-25-040441
SEC(opens sec.gov)
Jun 264
Craig Adam R0000899243-23-016480
SEC(opens sec.gov)
Mar 164
Craig Adam R0000899243-23-008753
SEC(opens sec.gov)
Jan 264
Craig Adam R0000891293-23-000004
SEC(opens sec.gov)

Companies

Address

C/O X4 PHARMACEUTICALS INC. 61 NORTH BEACON STREET, 4TH FLOOR

BOSTON, MA, 02134